Jump to Main Content


ASH Clinical Practice Guidelines

ASH Guidelines are developed by leading clinical, methodological, and patient experts through a rigorous process to review evidence and write actionable recommendations. Our state-of-the-art methodology ensures that they meet the highest standards for trustworthiness and transparency. Guideline panels are explicit about how recommendations were determined and open about the quality of evidence that factored into the final decision-making process.

Browse the existing guidelines below, and learn about guidelines currently in development, including those open for public comment.

Acute Myeloid Leukemia

Guidelines covering the treatment of acute myeloid leukemia in older adults. These guidelines update and augment the ASH AML guidelines published in 2020.


Two guidelines covering alternative screening and diagnostic tests and testing strategies during the initial evaluation and workup of amyloidosis, and the treatment of AL amyloidosis.

Aplastic Anemia

Guidelines for aplastic anemia covering diagnosis, transplant, medical management of immunosuppressive therapies for adult and pediatric populations.

Iron Deficiency Anemia

Guidelines scope and plan to be determined in 2024.

Immune Thrombocytopenia

Guidelines covering second-line therapies for ITP in adult populations . These guidelines will update and augment ASH ITP guidelines for adult and pediatric populations that were published in 2019.

Management of Cancer-Associated Anemia

Guidelines to address management of cancer-related anemia, in collaboration with the American Society of Clinical Oncology (ASCO).


Guidelines scope and plan to be determined in 2024.

Sickle Cell Disease

Five ASH Sickle Cell Disease Guidelines covering cardiopulmonary and kidney disease, cerebrovascular disease, transfusion, transplantation, and pain management.

Venous Thromboembolism

Ten guidelines covering prophylaxis for medical patients, diagnosis, anticoagulation therapy, heparin-induced thrombocytopenia, pregnancy, pediatrics, treatment, cancer, thrombophilia, prophylaxis in surgical patients, and anticoagulation in COVID-19 patients.

Von Willebrand Disease

Two guidelines on the diagnosis and management of VWD, in collaboration with the International Society on Thrombosis and Haemostasis (ISTH), National Hemophilia Foundation (NHF), and World Federation of Hemophilia (WFH).


If you have questions or need assistance with any aspect of the guideline topic proposal form, please email [email protected].

Topic Proposal

Interested in submitting a guideline topic? Want to contribute to guideline development?

Learn more

Public Comment

All are welcome to comment on draft recommendations, including physicians, patients, caregivers, and members of the public.

Review Draft Guidelines

user guide to Guidelines 

Learn how patients, clinicians, policymakers, researchers, and others may interpret and apply guideline information.

Learn more